FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2913333080> ?p ?o ?g. }

• W2913333080 endingPage "1075" @default.
• W2913333080 startingPage "1064" @default.
• W2913333080 abstract "Poly(ADP-ribose) polymerase (PARP) enzymes play an important role in repairing DNA damage and maintaining genomic stability. Olaparib, the first-in-class PARP inhibitor, has shown remarkable clinical benefits in the treatment of BRCA-mutated ovarian or breast cancer. However, the undesirable hematological toxicity and pharmacokinetic properties of olaparib limit its clinical application. Here, we report the first preclinical characterization of fluzoparib (code name: SHR-3162), a novel, potent, and orally available inhibitor of PARP. Fluzoparib potently inhibited PARP1 enzyme activity and induced DNA double-strand breaks, G2 /M arrest, and apoptosis in homologous recombination repair (HR)-deficient cells. Fluzoparib preferentially inhibited the proliferation of HR-deficient cells and sensitized both HR-deficient and HR-proficient cells to cytotoxic drugs. Notably, fluzoparib showed good pharmacokinetic properties, favorable toxicity profile, and superior antitumor activity in HR-deficient xenografts models. Furthermore, fluzoparib in combination with apatinib or with apatinib plus paclitaxel elicited significantly improved antitumor responses without extra toxicity. Based on these findings, studies to evaluate the efficacy and safety of fluzoparib (phase II) and those two combinations (phase I) have been initiated. Taken together, our results implicate fluzoparib as a novel attractive PARP inhibitor." @default.
• W2913333080 created "2019-02-21" @default.
• W2913333080 creator A5004086293 @default.
• W2913333080 creator A5014461673 @default.
• W2913333080 creator A5016715625 @default.
• W2913333080 creator A5019861824 @default.
• W2913333080 creator A5036822470 @default.
• W2913333080 creator A5047491476 @default.
• W2913333080 creator A5067620201 @default.
• W2913333080 creator A5073216396 @default.
• W2913333080 creator A5074004084 @default.
• W2913333080 creator A5087527472 @default.
• W2913333080 date "2019-02-19" @default.
• W2913333080 modified "2023-10-03" @default.
• W2913333080 title "Pharmacologic characterization of fluzoparib, a novel poly(ADP-ribose) polymerase inhibitor undergoing clinical trials" @default.
• W2913333080 cites W1882891727 @default.
• W2913333080 cites W1973268287 @default.
• W2913333080 cites W1986786529 @default.
• W2913333080 cites W2009007206 @default.
• W2913333080 cites W2061762018 @default.
• W2913333080 cites W2072528578 @default.
• W2913333080 cites W2086038769 @default.
• W2913333080 cites W2113467627 @default.
• W2913333080 cites W2136689090 @default.
• W2913333080 cites W2166071408 @default.
• W2913333080 cites W2171972386 @default.
• W2913333080 cites W2173456459 @default.
• W2913333080 cites W2177419974 @default.
• W2913333080 cites W2318905487 @default.
• W2913333080 cites W2528228811 @default.
• W2913333080 cites W2548423821 @default.
• W2913333080 cites W2607404840 @default.
• W2913333080 cites W2728245744 @default.
• W2913333080 cites W2737389832 @default.
• W2913333080 cites W2754327139 @default.
• W2913333080 cites W2761059676 @default.
• W2913333080 cites W2767110284 @default.
• W2913333080 cites W2907133739 @default.
• W2913333080 cites W4210281635 @default.
• W2913333080 doi "https://doi.org/10.1111/cas.13947" @default.
• W2913333080 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6398880" @default.
• W2913333080 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30663191" @default.
• W2913333080 hasPublicationYear "2019" @default.
• W2913333080 type Work @default.
• W2913333080 sameAs 2913333080 @default.
• W2913333080 citedByCount "50" @default.
• W2913333080 countsByYear W29133330802019 @default.
• W2913333080 countsByYear W29133330802020 @default.
• W2913333080 countsByYear W29133330802021 @default.
• W2913333080 countsByYear W29133330802022 @default.
• W2913333080 countsByYear W29133330802023 @default.
• W2913333080 crossrefType "journal-article" @default.
• W2913333080 hasAuthorship W2913333080A5004086293 @default.
• W2913333080 hasAuthorship W2913333080A5014461673 @default.
• W2913333080 hasAuthorship W2913333080A5016715625 @default.
• W2913333080 hasAuthorship W2913333080A5019861824 @default.
• W2913333080 hasAuthorship W2913333080A5036822470 @default.
• W2913333080 hasAuthorship W2913333080A5047491476 @default.
• W2913333080 hasAuthorship W2913333080A5067620201 @default.
• W2913333080 hasAuthorship W2913333080A5073216396 @default.
• W2913333080 hasAuthorship W2913333080A5074004084 @default.
• W2913333080 hasAuthorship W2913333080A5087527472 @default.
• W2913333080 hasBestOaLocation W29133330801 @default.
• W2913333080 hasConcept C126322002 @default.
• W2913333080 hasConcept C181199279 @default.
• W2913333080 hasConcept C182979987 @default.
• W2913333080 hasConcept C185592680 @default.
• W2913333080 hasConcept C2779138821 @default.
• W2913333080 hasConcept C535046627 @default.
• W2913333080 hasConcept C55493867 @default.
• W2913333080 hasConcept C71924100 @default.
• W2913333080 hasConcept C82381507 @default.
• W2913333080 hasConcept C98274493 @default.
• W2913333080 hasConceptScore W2913333080C126322002 @default.
• W2913333080 hasConceptScore W2913333080C181199279 @default.
• W2913333080 hasConceptScore W2913333080C182979987 @default.
• W2913333080 hasConceptScore W2913333080C185592680 @default.
• W2913333080 hasConceptScore W2913333080C2779138821 @default.
• W2913333080 hasConceptScore W2913333080C535046627 @default.
• W2913333080 hasConceptScore W2913333080C55493867 @default.
• W2913333080 hasConceptScore W2913333080C71924100 @default.
• W2913333080 hasConceptScore W2913333080C82381507 @default.
• W2913333080 hasConceptScore W2913333080C98274493 @default.
• W2913333080 hasFunder F4320321001 @default.
• W2913333080 hasFunder F4320321885 @default.
• W2913333080 hasFunder F4320325440 @default.
• W2913333080 hasIssue "3" @default.
• W2913333080 hasLocation W29133330801 @default.
• W2913333080 hasLocation W29133330802 @default.
• W2913333080 hasLocation W29133330803 @default.
• W2913333080 hasOpenAccess W2913333080 @default.
• W2913333080 hasPrimaryLocation W29133330801 @default.
• W2913333080 hasRelatedWork W1964337584 @default.
• W2913333080 hasRelatedWork W1990291556 @default.
• W2913333080 hasRelatedWork W2061827661 @default.
• W2913333080 hasRelatedWork W2511046386 @default.
• W2913333080 hasRelatedWork W2533307528 @default.
• W2913333080 hasRelatedWork W2604684522 @default.

• next